MAIA Biotechnology (MAIA) announced that the FDA has granted fast track designation for ateganosine for the treatment of non-small cell lung cancer. Ateganosine is currently being evaluated in a pivotal Phase 2 THIO-101 clinical trial evaluating its anti-tumor activity when followed by a checkpoint inhibitor.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MAIA:
- MAIA Biotechnology Publishes Promising Preclinical Cancer Data
- MAIA Biotechnology announces publication of ateganosine prodrug data
- MAIA Biotechnology Begins Phase 2 Trial Expansion
- MAIA Biotechnology doses first patient in Taiwan in THIO-101 trial
- MAIA Biotechnology Enters Stock Purchase Agreement with Prevail